CoChat

HER3 Is an Actionable Target in Advanced Prostate Cancer

Open access
Gil, Veronica, Miranda, Susana, Riisnaes, Ruth, Gurel, Bora, D’Ambrosio, Mariantonietta, Vasciaveo, Alessandro, Crespo, Mateus, Ferreira, Ana, Brina, Daniela, Troiani, Martina, Sharp, Adam, Sheehan, Beshara, Christova, Rossitza, Seed, George, Figueiredo, Ines, Lambros, Maryou, Dolling, David, Rekowski, Jan, Alajati, Abdullah, Clarke, Matthew, Pereira, Rita, Flohr, Penny, Fowler, Gemma, Boysen, Gunther, Sumanasuriya, Semini, Bianchini, Diletta, Rescigno, Pasquale, Aversa, Caterina, Tunariu, Nina, Guo, Christina, Paschalis, Alec, Bertan, Claudia, Buroni, Lorenzo, Ning, Jian, Carreira, Suzanne, Workman, Paul, Swain, Amanda, Califano, Andrea, Shen, Michael M., Alimonti, Andrea, Neeb, Antje, PCF/SU2C International Prostate Cancer Dream Team, Welti, Jonathan, Yuan, Wei, de Bono, Johann · 2021 · Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is commonly highly expressed in lethal prostate cancer, associating with reduced time to castration resistance (CR) and survival. Multiplex immunofluorescence indicated that the HER3 ligand NRG1 is detectable primarily in tumor-infiltrating myelomonocytic cells in human prostate cancer; this observation was confirmed using single-cell RNA sequencing of human prostate cancer biopsies and murine transgenic prostate cancer models. In castration-resistant prostate cancer (CRPC) patient-derived xenograft organoids with high HER3 expression as well as mouse prostate cancer organoids, recombinant NRG1 enhanced proliferation and survival. Supernatant from murine bone marrow–derived macrophages and myeloid-derived suppressor cells promoted murine prostate cancer organoid growth in vitro, which could be reversed by a neutralizing anti-NRG1 antibody and ERBB inhibition. Targeting HER3, especially with the HER3-directed antibody–drug conjugate U3-1402, exhibited antitumor activity against HER3-expressing prostate cancer. Overall, these data indicate that HER3 is commonly overexpressed in lethal prostate cancer and can be activated by NRG1 secreted by myelomonocytic cells in the tumor microenvironment, supporting HER3-targeted therapeutic strategies for treating HER3-expressing advanced CRPC. Significance: HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-21-3360

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. HER3 expression in lethal prostate cancer has clinical relevance. A and B, Transcriptome analyses of RNA-seq data from 159 CRPC biopsies (PCF/SU2C International Prostate Cancer Dream Team) for ERBB family member expression (FPKM; A) and comparison of ERBB3/HER3 (x-axis) and ERBB2/HER2 (y-axis) mRNA expression in same patient samples showing a statistically significant positive correlation (Spearman r = 0.4370928; B). C, Representative IHC images of HER2 (left) and HER3 (right) protein detection in same patient CSPC and CRPC biopsies (scale bar, 100 μm), with membranous OD shown for each in top right corners. D, Kaplan–Meier curves for time to CRPC from diagnosis of prostate cancer for membranous HER2 expression by median OD (155.5; left) and membranous HER3 expression by median OD (2958.0; right). HER3 but not HER2 protein expression by IHC associates with time to CRPC. HR with 95% CIs and P values for univariate Cox survival model is shown. E, Kaplan–Meier curves for OS, from diagnosis of prostate cancer for membranous HER2 expression by median OD (155.5; left) and membranous HER3 expression by median OD (2958.0; right). HER3 but not HER2 protein expression by IHC associates with OS. HR with 95% CIs and P values for univariate Cox survival model are shown.
Figure 1. HER3 expression in lethal prostate cancer has clinical relevance. A and B, Transcriptome analyses of RNA-seq data from 159 CRPC biopsies (PCF/SU2C International Prostate Cancer Dream Team) for ERBB family member expression (FPKM; A) and comparison of ERBB3/HER3 (x-axis) and ERBB2/HER2 (y-axis) mRNA expression in same patient samples showing a statistically significant positive correlation (Spearman r = 0.4370928; B). C, Representative IHC images of HER2 (left) and HER3 (right) protein detection in same patient CSPC and CRPC biopsies (scale bar, 100 μm), with membranous OD shown for each in top right corners. D, Kaplan–Meier curves for time to CRPC from diagnosis of prostate cancer for membranous HER2 expression by median OD (155.5; left) and membranous HER3 expression by median OD (2958.0; right). HER3 but not HER2 protein expression by IHC associates with time to CRPC. HR with 95% CIs and P values for univariate Cox survival model is shown. E, Kaplan–Meier curves for OS, from diagnosis of prostate cancer for membranous HER2 expression by median OD (155.5; left) and membranous HER3 expression by median OD (2958.0; right). HER3 but not HER2 protein expression by IHC associates with OS. HR with 95% CIs and P values for univariate Cox survival model are shown.CC BY-NC-ND · PubMed Central
Figure 2. Upregulation of HER3 expression in CRPC models. A and B, AR, ARv7, EGFR, HER2, HER3, and NRG1 protein expression by IHC on PDX tumor samples developed in intact and castrated mice for CP50 (A) and CP142 (B). Scale bar, 50 μm. C and D, Western blot analysis showing AR, ARv7, NRG1, and ERBB receptors expression and phospho-AKT pathway activation in same models as A to B. n.d., proteins below detection level. E and F, Transcriptome analyses of RNA-seq data on intact (n = 3; left) and castrate (n = 3; right) PDX tumor samples, for ERBB family member and NRG1 and NRG2 ligands expression (FPKM), divided into very high (upper 25% expressed genes), medium high (50%–75% expressed genes), medium low (25%–50% expressed genes), and very low (lower 25% expressed genes), in same models as A and B.
Figure 2. Upregulation of HER3 expression in CRPC models. A and B, AR, ARv7, EGFR, HER2, HER3, and NRG1 protein expression by IHC on PDX tumor samples developed in intact and castrated mice for CP50 (A) and CP142 (B). Scale bar, 50 μm. C and D, Western blot analysis showing AR, ARv7, NRG1, and ERBB receptors expression and phospho-AKT pathway activation in same models as A to B. n.d., proteins below detection level. E and F, Transcriptome analyses of RNA-seq data on intact (n = 3; left) and castrate (n = 3; right) PDX tumor samples, for ERBB family member and NRG1 and NRG2 ligands expression (FPKM), divided into very high (upper 25% expressed genes), medium high (50%–75% expressed genes), medium low (25%–50% expressed genes), and very low (lower 25% expressed genes), in same models as A and B.CC BY-NC-ND · PubMed Central
Figure 3. NRG-activated HER3 signaling in lethal PC. A, Representative micrographs of prostate cancer patient samples, showing NRG1 protein expression, by IHC and IF, in CD11b (green) and CD68 (yellow) positive inflammatory cells. Scale bar, 50 μm. B, NRG1 protein expression, by IHC, in prostatic adenocarcinoma samples, CSPC (left; n = 24) and CRPC (right; n = 34), showing significantly higher expression in inflammatory cells (red) compared with tumor (gray; Mann–Whitney test, P values: **, P ≤ 0.01; ****, P ≤ 0.0001, median H-score, and interquartile range shown) and showing significantly higher expression in inflammatory cells present in CRPC, compared with inflammatory cells present in CSPC. No significant differences were observed between CSPC and CRPC tumor cells (Mann–Whitney test, P values: **, P ≤ 0.01; ****, P ≤ 0.0001; ns, nonsignificant). C, UMAP projection of 30,329 single-cell gene expression profiles from 12 primary and one lymph node metastasis tissue samples (n = 13) of 12 patients with prostate cancer color-coded per sample. D, Leiden algorithm identifies eight clusters. Clusters are color coded by SingleR-inferred cell subtype. E, Violin plots depicting NRG1 expression levels per assigned cell subtype. F, Violin plot representing frequency of immune, epithelial, and stroma cells expressing NRG1 and NRG2 subtypes from FACS sorted from murine prostate tumors Pten−/− followed by single-cell transcriptome analysis (n = 2). G, RNA-seq of FACS-sorted murine BM-derived MDSCs, heatmap of log-CPM values for NRG1 genes in M-MDSCs, PMN-MDSCs, and BM (n = 3; FDR adjusted, P < 0.05). H, Relative luminescence (RLU) as a measure for mouse prostate organoid proliferation within 5 days in conditional media generated from C57BL/6N mice BM-differentiated MDSCs and macrophages. Baseline organoid media as vehicle control with and without rNRG1 (ordinary two-way ANOVA with Tukey correction test, P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). I, Experimental validation of functional NRG1 in conditional media from MDSCs and macrophages by antibody neutralization at 3 μg (Heregulin 2573; Cell Signaling Technology). Luminescence readings at 5 days (ordinary two-way ANOVA with Tukey correction test, P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
Figure 3. NRG-activated HER3 signaling in lethal PC. A, Representative micrographs of prostate cancer patient samples, showing NRG1 protein expression, by IHC and IF, in CD11b (green) and CD68 (yellow) positive inflammatory cells. Scale bar, 50 μm. B, NRG1 protein expression, by IHC, in prostatic adenocarcinoma samples, CSPC (left; n = 24) and CRPC (right; n = 34), showing significantly higher expression in inflammatory cells (red) compared with tumor (gray; Mann–Whitney test, P values: **, P ≤ 0.01; ****, P ≤ 0.0001, median H-score, and interquartile range shown) and showing significantly higher expression in inflammatory cells present in CRPC, compared with inflammatory cells present in CSPC. No significant differences were observed between CSPC and CRPC tumor cells (Mann–Whitney test, P values: **, P ≤ 0.01; ****, P ≤ 0.0001; ns, nonsignificant). C, UMAP projection of 30,329 single-cell gene expression profiles from 12 primary and one lymph node metastasis tissue samples (n = 13) of 12 patients with prostate cancer color-coded per sample. D, Leiden algorithm identifies eight clusters. Clusters are color coded by SingleR-inferred cell subtype. E, Violin plots depicting NRG1 expression levels per assigned cell subtype. F, Violin plot representing frequency of immune, epithelial, and stroma cells expressing NRG1 and NRG2 subtypes from FACS sorted from murine prostate tumors Pten−/− followed by single-cell transcriptome analysis (n = 2). G, RNA-seq of FACS-sorted murine BM-derived MDSCs, heatmap of log-CPM values for NRG1 genes in M-MDSCs, PMN-MDSCs, and BM (n = 3; FDR adjusted, P < 0.05). H, Relative luminescence (RLU) as a measure for mouse prostate organoid proliferation within 5 days in conditional media generated from C57BL/6N mice BM-differentiated MDSCs and macrophages. Baseline organoid media as vehicle control with and without rNRG1 (ordinary two-way ANOVA with Tukey correction test, P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). I, Experimental validation of functional NRG1 in conditional media from MDSCs and macrophages by antibody neutralization at 3 μg (Heregulin 2573; Cell Signaling Technology). Luminescence readings at 5 days (ordinary two-way ANOVA with Tukey correction test, P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).CC BY-NC-ND · PubMed Central
Figure 4. Antitumor activity of anti-HER3 ADC U3-1402. A, Organoid proliferation normalized to untreated vehicle in PDX-O models CP50 and CP142 (n = 3) monitored for 7 days with and without additional rNRG1 (100 ng/mL). ANOVA with Sidak correction test was applied; P value: ****, P ≤ 0.0001 (left). Immunoblots depicting phosphorylated-HER3 expression with additional rNRG1 in CP50 and CP142 PDX-O CRPC models after 16-hour treatment with human rNRG1 (100 ng/mL). GAPDH was used as loading control (right). n.d., below detection level. B,In vitro cell growth inhibitory activity of the anti-HER3 ADC U3-1402 (red line) and the anti-HER3 antibody without payload U3-1287 (patritumab; green line) in the PDX-O model CP50 (left) and CP142 (right), monitored for 7 days with endpoint assay luminescence. All results are expressed as mean ± SEM (n = 3). Statistical significance was analyzed using ANOVA with Dunnett multiple comparisons correction test to analyze mean difference per concentration of U3-1402 and U3-1287 (patritumab) versus IgG-ADC control (MAAA-9289; blue line), P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. C,In vivo efficacy of the anti-HER3 ADC U3-1402 (10 mg/kg; red line) in PDX models CP50 (left) and CP142 (right); the anti-HER3 antibody without payload U3-1287 (patritumab; 10 mg/kg, green line) and IgG-ADC (MAAA-9289; 10 mg/kg, purple line) are also shown. CP50-PDX treated with U3-1402 was monitored for 5 weeks post-dosing (P value: ***, P ≤ 0.001; n.s., nonsignificant) and treatment was administered weekly for a total of five times (black arrows) while CP142-PDX received a total of three weekly doses. Vehicle, 10 mmol/L acetate buffer-5% sorbitol-pH 5.5 (blue line). All results were expressed as mean ± SEM (n = 10) and statistical significance was analyzed using ANOVA with Dunnett multiple comparisons correction test to analyze mean difference of each treatment versus vehicle control 7 days post-treatment, corresponding to last tumor measurement.
Figure 4. Antitumor activity of anti-HER3 ADC U3-1402. A, Organoid proliferation normalized to untreated vehicle in PDX-O models CP50 and CP142 (n = 3) monitored for 7 days with and without additional rNRG1 (100 ng/mL). ANOVA with Sidak correction test was applied; P value: ****, P ≤ 0.0001 (left). Immunoblots depicting phosphorylated-HER3 expression with additional rNRG1 in CP50 and CP142 PDX-O CRPC models after 16-hour treatment with human rNRG1 (100 ng/mL). GAPDH was used as loading control (right). n.d., below detection level. B,In vitro cell growth inhibitory activity of the anti-HER3 ADC U3-1402 (red line) and the anti-HER3 antibody without payload U3-1287 (patritumab; green line) in the PDX-O model CP50 (left) and CP142 (right), monitored for 7 days with endpoint assay luminescence. All results are expressed as mean ± SEM (n = 3). Statistical significance was analyzed using ANOVA with Dunnett multiple comparisons correction test to analyze mean difference per concentration of U3-1402 and U3-1287 (patritumab) versus IgG-ADC control (MAAA-9289; blue line), P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. C,In vivo efficacy of the anti-HER3 ADC U3-1402 (10 mg/kg; red line) in PDX models CP50 (left) and CP142 (right); the anti-HER3 antibody without payload U3-1287 (patritumab; 10 mg/kg, green line) and IgG-ADC (MAAA-9289; 10 mg/kg, purple line) are also shown. CP50-PDX treated with U3-1402 was monitored for 5 weeks post-dosing (P value: ***, P ≤ 0.001; n.s., nonsignificant) and treatment was administered weekly for a total of five times (black arrows) while CP142-PDX received a total of three weekly doses. Vehicle, 10 mmol/L acetate buffer-5% sorbitol-pH 5.5 (blue line). All results were expressed as mean ± SEM (n = 10) and statistical significance was analyzed using ANOVA with Dunnett multiple comparisons correction test to analyze mean difference of each treatment versus vehicle control 7 days post-treatment, corresponding to last tumor measurement.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 72

Metadata

Authors
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., Clarke, M., Pereira, R., Flohr, P., Fowler, G., Boysen, G., Sumanasuriya, S., Bianchini, D., Rescigno, P., Aversa, C., Tunariu, N., Guo, C., Paschalis, A., Bertan, C., Buroni, L., Ning, J., Carreira, S., Workman, P., Swain, A., Califano, A., Shen, M. M., Alimonti, A., Neeb, A., PCF/SU2C International Prostate Cancer Dream Team, Welti, J., Yuan, W., & de Bono, J.
Affiliations
  • Institute of Cancer Research (GB)
  • 1The Institute of Cancer Research, London, United Kingdom.
  • Institute of Oncology Research (CH)
  • Columbia University (US)
Venue
Cancer Research
Published
2021-11-09
Volume
81
Issue
24
Pages
6207-6218
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W3214083702
Cited by
68
References
49
Citations by year
2026: 9 · 2025: 19 · 2024: 19 · 2023: 14 · 2022: 7
FWCI
7.12
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
Funders
  • Prostate Cancer UK (CEO13-3-002, TLD-PF19-005)
  • U.S. Department of Defense (W81XWH19-1-0337)
  • Prostate Cancer Foundation (20131017, 20131017-1)
  • Stand Up To Cancer (SU2C-AACR-DT0712)
  • Cancer Research UK (CRM108X-A25144)
  • Imperial Experimental Cancer Medicine Centre (ECMC-CRM064X)
  • Daiichi Sankyo Company
  • Medical Research Council
  • Wellcome Trust Centre for Mitochondrial Research
  • Chordoma Foundation
  • Mark Foundation For Cancer Research
  • Academy of Medical Sciences
  • National Cancer Institute (R35 CA197745)
  • National Institutes of Health (R01 CA251527)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
HER3, advanced prostate cancer, castration-resistant prostate cancer, neuregulin-1, ErbB signaling, myelomonocytic cells, tumor microenvironment, macrophages, myeloid-derived suppressor cells, patient-derived xenografts
MeSH terms
Antineoplastic Agents, Immunological, Animals, Camptothecin, Follow-Up Studies, Humans, Male, Organoids, Prognosis, Prospective Studies, Prostatic Neoplasms, Tumor Cells, Cultured, Biomarkers, Tumor, Survival Rate, Mice, SCID, Mice, Inbred NOD, Apoptosis, Neuregulin-1, Receptor, ErbB-3, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Tumor Microenvironment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER3 Is an Actionable Target in Advanced Prostate Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-3360
The paper
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., . . . de Bono, J. (2021). HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-3360

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.